
argenx acquires Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
At ESC Congress 2026, incretin-based therapies, including GLP-1 receptor agonists, featured across heart failure (HF), chronic kidney disease (CKD), atrial fibrillation (AF), obesity and cardiovascular prevention, reflecting their continued evolution from metabolic drugs into broader cardiometabolic therapies.






